IN2012DN01769A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01769A IN2012DN01769A IN1769DEN2012A IN2012DN01769A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A IN 1769DEN2012 A IN1769DEN2012 A IN 1769DEN2012A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A
- Authority
- IN
- India
- Prior art keywords
- antikine
- mip
- antibodies
- lß7ccl4
- ccl3
- Prior art date
Links
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 abstract 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
- 108010040471 CC Chemokines Proteins 0.000 abstract 1
- 102000001902 CC Chemokines Human genes 0.000 abstract 1
- 108010055166 Chemokine CCL5 Proteins 0.000 abstract 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 abstract 1
- 230000009824 affinity maturation Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23801509P | 2009-08-28 | 2009-08-28 | |
| PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01769A true IN2012DN01769A (pl) | 2015-06-05 |
Family
ID=43628404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1769DEN2012 IN2012DN01769A (pl) | 2009-08-28 | 2010-08-27 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8313747B2 (pl) |
| EP (1) | EP2470671B1 (pl) |
| JP (2) | JP6109571B2 (pl) |
| KR (1) | KR101778813B1 (pl) |
| CN (1) | CN102782148B (pl) |
| AU (1) | AU2010286516B2 (pl) |
| BR (1) | BR112012004387A2 (pl) |
| CA (1) | CA2771781C (pl) |
| DK (1) | DK2470671T3 (pl) |
| ES (1) | ES2531561T3 (pl) |
| HR (1) | HRP20150162T1 (pl) |
| IN (1) | IN2012DN01769A (pl) |
| MX (1) | MX2012002427A (pl) |
| PL (1) | PL2470671T3 (pl) |
| PT (1) | PT2470671E (pl) |
| SI (1) | SI2470671T1 (pl) |
| SM (1) | SMT201500011B (pl) |
| WO (1) | WO2011025962A1 (pl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2470671T3 (pl) * | 2009-08-28 | 2015-05-29 | Regeneron Pharma | Przeciwciała antykinowe wiążące się z wieloma chemokinami CC |
| CN103857421B (zh) * | 2011-06-13 | 2017-09-22 | Tla指标免疫疗法公司 | 治疗癌症的方法和在其中使用的结合试剂 |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| EP2763540A4 (en) * | 2011-09-09 | 2015-04-22 | Univ Yale | COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES |
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| TWI612059B (zh) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 |
| MX371412B (es) | 2013-05-23 | 2020-01-29 | Shire Human Genetic Therapies | ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA. |
| JP6220222B2 (ja) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品 |
| KR20210125114A (ko) * | 2013-12-09 | 2021-10-15 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
| CA2939931C (en) | 2014-02-28 | 2025-04-22 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8 |
| DK3114139T3 (da) | 2014-03-04 | 2022-09-12 | Chemomab Ltd | Anti eotaxin-2 antistoffer, der genkender supplerende ccr3-bindende chemokiner |
| CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
| TWI566780B (zh) * | 2014-10-24 | 2017-01-21 | 國立陽明大學 | 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途 |
| IL282649B (en) | 2014-12-09 | 2022-07-01 | Regeneron Pharma | Non-human animals with a humanized gene for differentiation cluster 274 |
| AU2016278239B9 (en) | 2015-06-17 | 2022-08-11 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| US11733232B2 (en) | 2017-03-01 | 2023-08-22 | National University Corporation Hokkaido University | Method for producing disease modeling non-human animal, disease modeling non-human animal, and method for screening drug and method for determining risk of disease using the same |
| AU2018248672B2 (en) * | 2017-04-05 | 2021-09-30 | Korea Research Institute Of Bioscience And Biotechnology | NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same |
| EA201992626A1 (ru) | 2017-05-05 | 2020-04-24 | Аллакос Инк. | Способы и композиции для лечения аллергических заболеваний глаз |
| WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
| EP3694887A4 (en) * | 2017-10-13 | 2022-02-23 | A & G Pharmaceutical, Inc. | MONOCLONAL ANTIBODIES AND CONJUGATES TO PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF |
| CN112041341B (zh) * | 2017-12-28 | 2024-05-24 | 机敏医药股份有限公司 | Ccl14的抗体和检测 |
| US12352758B2 (en) | 2018-02-26 | 2025-07-08 | Cornell University | Quantitative biomarkers of EHV-1 susceptibility and protection |
| CA3099974A1 (en) * | 2018-05-11 | 2019-11-14 | Halcyon Therapeutics, Inc. | Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
| KR102489282B1 (ko) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물 |
| US20220356238A1 (en) * | 2019-07-02 | 2022-11-10 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN113893331B (zh) * | 2020-07-06 | 2024-11-26 | 中国农业科学院特产研究所 | 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用 |
| EP4178614A4 (en) * | 2020-07-08 | 2024-10-30 | Georgia Tech Research Corporation | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF SARS-COV-2 VIRUS INFECTIONS |
| MX2023004349A (es) * | 2020-10-16 | 2023-08-22 | Lanova Medicines Ltd | Anticuerpos monoclonales anti-ccr8 y sus usos. |
| CN115598111B (zh) * | 2021-07-08 | 2025-03-25 | 南京大学 | 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法 |
| CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| UA87979C2 (ru) | 2002-08-19 | 2009-09-10 | Астразенека Аб | Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1) |
| US7888479B2 (en) | 2002-11-27 | 2011-02-15 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactric proteins |
| WO2006067124A2 (en) * | 2004-12-21 | 2006-06-29 | Laboratoires Serono S.A. | Cc-chemokine antagonists |
| CN101802211B (zh) * | 2007-08-02 | 2014-10-01 | 诺维莫尼公司 | 抗正常t细胞表达和分泌活化调节因子(rantes)抗体及其使用方法 |
| PL2470671T3 (pl) * | 2009-08-28 | 2015-05-29 | Regeneron Pharma | Przeciwciała antykinowe wiążące się z wieloma chemokinami CC |
-
2010
- 2010-08-27 PL PL10812667T patent/PL2470671T3/pl unknown
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/es active Active
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/ja active Active
- 2010-08-27 SI SI201030901T patent/SI2470671T1/sl unknown
- 2010-08-27 HR HRP20150162TT patent/HRP20150162T1/hr unknown
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en not_active Ceased
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/ko not_active Expired - Fee Related
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/pt active Search and Examination
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 PT PT10812667T patent/PT2470671E/pt unknown
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/es active IP Right Grant
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/zh not_active Expired - Fee Related
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/xx unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL2470671T3 (pl) | 2015-05-29 |
| US8313747B2 (en) | 2012-11-20 |
| CN102782148B (zh) | 2016-04-20 |
| CA2771781C (en) | 2019-01-15 |
| US20150166647A1 (en) | 2015-06-18 |
| PT2470671E (pt) | 2015-02-05 |
| AU2010286516A2 (en) | 2012-06-14 |
| US20130108640A1 (en) | 2013-05-02 |
| EP2470671B1 (en) | 2014-12-24 |
| JP2016135783A (ja) | 2016-07-28 |
| SI2470671T1 (sl) | 2015-04-30 |
| ES2531561T3 (es) | 2015-03-17 |
| CA2771781A1 (en) | 2011-03-03 |
| RU2012111820A (ru) | 2013-10-10 |
| KR101778813B1 (ko) | 2017-09-14 |
| CN102782148A (zh) | 2012-11-14 |
| KR20120091013A (ko) | 2012-08-17 |
| US20110059107A1 (en) | 2011-03-10 |
| AU2010286516B2 (en) | 2016-10-06 |
| JP6109571B2 (ja) | 2017-04-05 |
| EP2470671A1 (en) | 2012-07-04 |
| BR112012004387A2 (pt) | 2015-09-08 |
| AU2010286516A1 (en) | 2012-03-08 |
| HRP20150162T1 (hr) | 2015-05-08 |
| WO2011025962A1 (en) | 2011-03-03 |
| SMT201500011B (it) | 2015-03-05 |
| EP2470671A4 (en) | 2013-04-03 |
| US9005617B2 (en) | 2015-04-14 |
| JP2013503192A (ja) | 2013-01-31 |
| DK2470671T3 (en) | 2015-02-09 |
| MX2012002427A (es) | 2012-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01769A (pl) | ||
| EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| AR096713A1 (es) | Proceso de purificación para anticuerpos monoclonales | |
| TN2014000107A1 (en) | Anti-aplhabetatcr antibody | |
| CO2019001246A2 (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
| MX2010007935A (es) | Anticuerpo monoclonal humanizado anti-nkg2a humano. | |
| AU2018200640B2 (en) | Humanization of rabbit antibodies using a universal antibody framework | |
| WO2010039900A3 (en) | Non-human mammals for the production of chimeric antibodies | |
| DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
| MX2012000841A (es) | Optimizacion de la produccion de anticuerpos. | |
| PH12019502730A1 (en) | Method of manufacturing bispecific antibodies and therapeutic use of such antibodies | |
| MX2011003855A (es) | Metodos para producir anticuerpos a partir de celulas plasmaticas. | |
| MX2013003182A (es) | Purificacion de anticuerpos por cromatografia de lecho movil simulada. | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| MX337684B (es) | Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f. | |
| NZ706189A (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
| WO2009130459A3 (en) | Epitopes of il-17a and il-17f and antibodies specific thereto | |
| NZ588469A (en) | Antibodies to il-6 and their uses | |
| MX366112B (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
| IN2009DN05722A (pl) | ||
| MX337203B (es) | Novedosas moleculas inhbidoras de jnk. | |
| UA105405C2 (ru) | Гуманизированное антитело против человеческого il-22ra | |
| WO2020247929A8 (en) | High affinity anti-cd3 antibodies, and methods for their generation and use | |
| PL2099812T3 (pl) | Sposób wytwarzania tagatozy z wykorzystaniem izomeryzacji galaktozy o wysokiej wydajności |